Windtree Therapeutics, Inc. (WINT)
After hours:
- GlobeNewswire
Windtree Therapeutics to Raise $1.0 Million From the Exercise of Previously Issued Warrants
WARRINGTON, Pa., Jan. 20, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NASDAQ: WINT) (“Windtree” or the “Company”) today announced it has entered into warrant inducement offer letters (the “Inducement Offer Letters”) to raise approximately $1.0 million in gross proceeds from the exercise of warrants to purchase 4,808,595 shares of the Company’s common stock, par value $0.001 per share (“Common Stock”), in the aggregate. Pursuant to the Inducement Offer Letters, the Company agreed to red
- GlobeNewswire
Nasdaq Grants Windtree Therapeutics 180-day Extension to Regain Compliance
WARRINGTON, Pa., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for cardiovascular disorders, today announced that the NASDAQ Stock Market (“Nasdaq”) has granted Windtree an additional 180 days to regain compliance with Nasdaq’s $1.00 minimum bid price rule requirement under Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”), following the expiration of
- Zacks
Windtree Therapeutics, Inc. (WINT) Upgraded to Buy: Here's Why
Windtree Therapeutics, Inc. (WINT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
